InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Latest quote
$14.08
+$0.07 · +0.50%
After-hours
$14.08
$0.00 · 0.00%
Oct 8, 4:38 PM ET
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
85
Deep Value
Sentiment
64
Bullish
Risk
41
Elevated Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Day range
Current $14.08
52-week range
Current $14.08
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 370.5M USD | 394.82M USD | 492.05M USD | 454.27M USD | 357.57M USD |
| Cost of goods sold | 79.53M USD | 77.75M USD | 80.71M USD | 73.49M USD | 53.59M USD |
| Gross profit | 290.97M USD | 317.07M USD | 411.34M USD | 380.79M USD | 303.97M USD |
| Research and development | 13.32M USD | 13.14M USD | 13.41M USD | 12.43M USD | 9.53M USD |
| Selling, general, and administrative | 192.26M USD | 191.4M USD | 202.27M USD | 170.51M USD | 127.76M USD |
| Operating expenses | 205.58M USD | 204.54M USD | 215.68M USD | 182.93M USD | 136.5M USD |
| Interest income | 24.94M USD | 30.94M USD | 21.61M USD | 3.61M USD | 525K USD |
| Depreciation and amortization | 695K USD | 728K USD | 623K USD | 680K USD | 517K USD |
| Operating income | 85.39M USD | 112.53M USD | 195.66M USD | 197.85M USD | 167.48M USD |
| Net income | 93.83M USD | 181.28M USD | 197.92M USD | 161.52M USD | 164.97M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$19.00
34.94% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 1, 2021 | 2:1 | — | — |
Effective Oct 1, 2021
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core MSCI EAFE ETFIEFA7.8M0.00%191.47B USD0.07%$95.87-0.34%
iShares MSCI EAFE Small-Cap ETFSCZ2.4M0.02%12.79B USD0.40%$83.25-0.44%
iShares Core MSCI Total International Stock ETFIXUS2.16M0.00%59.46B USD0.07%$94.14-0.80%
ARK Israel Innovative Technology ETFIZRL1.95M1.49%136.9M USD0.49%$27.91-0.06%
Avantis International Small Cap Value ETFAVDV1.47M0.01%19.99B USD0.36%$107.72-0.31%
iShares MSCI Israel ETFEIS1.43M0.17%876.03M USD0.59%$117.64-0.26%
iShares Core MSCI International Developed Markets ETFIDEV1.4M0.00%33.18B USD0.04%$88.56-0.26%
Schwab Fundamental International Small Company Index ETFFNDC1.4M0.05%3.08B USD0.39%$49.37-0.28%
iShares Core MSCI EAFE ETFIEFA
iShares MSCI EAFE Small-Cap ETFSCZ
iShares Core MSCI Total International Stock ETFIXUS
ARK Israel Innovative Technology ETFIZRL
Avantis International Small Cap Value ETFAVDV
iShares MSCI Israel ETFEIS
iShares Core MSCI International Developed Markets ETFIDEV
Schwab Fundamental International Small Company Index ETFFNDCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.